KEMSTRO Drug Patent Profile

When do Kemstro patents expire, and when can generic versions of Kemstro launch?

Kemstro is a drug marketed by Ucb Inc and is included in one NDA.

The generic ingredient in KEMSTRO is baclofen. There are twenty-one drug master file entries for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the baclofen profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Kemstro

A generic version of KEMSTRO was approved as baclofen by IVAX SUB TEVA PHARMS on July 21^st, 1988.

Summary for KEMSTRO

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	150
Clinical Trials:	3
Patent Applications:	5,102
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for KEMSTRO
DailyMed Link:	KEMSTRO at DailyMed

Recent Clinical Trials for KEMSTRO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pennsylvania Department of Health	Phase 2
National Institute on Drug Abuse (NIDA)	Phase 2
University of Pennsylvania	Phase 2

See all KEMSTRO clinical trials

US Patents and Regulatory Information for KEMSTRO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-001	Oct 30, 2003		DISCN	Yes	No
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-002	Oct 30, 2003		DISCN	Yes	No

Expired US Patents for KEMSTRO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-001	Oct 30, 2003	6,024,981
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-002	Oct 30, 2003	6,221,392
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-002	Oct 30, 2003	6,024,981
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-001	Oct 30, 2003	6,221,392

International Patents for KEMSTRO

See the table below for patents covering KEMSTRO around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2525720
Portugal	2147669
Japan	2008001726	RAPIDLY DISSOLVING ROBUST DOSAGE FORM
Denmark	2147669
Australia	6896998
European Patent Office	0975336
Japan	5072513

KEMSTRO Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Muscle Relaxant Drugs: A Case Study

Introduction

Muscle relaxant drugs are a crucial segment of the pharmaceutical industry, particularly given the rising prevalence of musculoskeletal disorders and chronic pain. This article will delve into the market dynamics and financial trajectory of muscle relaxant drugs, using the broader context to infer insights relevant to a specific drug like KEMSTRO.

Market Size and Growth

The muscle relaxant drugs market has been experiencing significant growth. As of 2022, the market size was valued at USD 4.1 billion and is projected to reach USD 9.4 billion by 2032, with a Compound Annual Growth Rate (CAGR) of 6.4% from 2023 to 2032[1].

Key Drivers of Growth

Several factors are driving this growth:

Rising Geriatric Population

The increasing age of the global population is a significant driver. Older individuals are more prone to musculoskeletal disorders, which in turn increases the demand for muscle relaxant drugs.

Growing Prevalence of Chronic Pain

Chronic pain, particularly lower back pain, is becoming more common. According to the World Health Organization (WHO), lower back pain affected nearly 619 million people globally in 2022 and is expected to increase to 843 million cases by 2050[1].

Advancements in Drug Discovery and Development

The surge in drug discovery and development activities is also propelling the market forward. Pharmaceutical companies are investing heavily in research and development to create more effective and targeted treatments.

Market Segmentation

The muscle relaxant drugs market is segmented based on several criteria:

Drug Type

This includes different types of muscle relaxants such as benzodiazepines, non-benzodiazepines, and others.

Dosage Form

The market is segmented into various dosage forms like tablets, capsules, and injectables.

Application

Muscle relaxants are used for various applications including musculoskeletal disorders, spinal injuries, and surgical procedures.

Route of Administration

The route of administration can be oral, parenteral, or topical.

Distribution Channel

The distribution channels include hospitals, pharmacies, and online platforms.

Financial Performance of Pharmaceutical Companies

To understand the financial trajectory, it's essential to look at the performance of pharmaceutical companies involved in this market.

Revenue Growth

Companies like Novartis have seen significant revenue growth in their innovative medicines segment. For instance, Novartis reported net sales from continuing operations of USD 11.8 billion in the first quarter of 2024, with a growth rate of 10% in constant currency[2].

Research and Development Expenses

Research and development (R&D) expenses are a critical component of the financial performance of pharmaceutical companies. For example, Cocrystal Pharma reported R&D expenses of $10.5 million for the first nine months of 2024, which is slightly lower than the previous year[5].

Operating Income and Profitability

The operating income of pharmaceutical companies can fluctuate based on various factors including sales growth, R&D investments, and generic competition. Novartis reported an operating income of USD 3.4 billion in the first quarter of 2024, with a margin of 28.5% of net sales[2].

Challenges and Pitfalls

Despite the growth, the market faces several challenges:

Generic Competition

The entry of generic drugs can erode the market share of branded products. This is particularly evident in the case of drugs like Lucentis and Gilenya, where generic competition has impacted sales[2].

High Development Costs

The development of new drugs, especially precision medicines, is costly and time-consuming. This can affect the financial trajectory of companies involved in such research[3].

Regulatory Hurdles

Pharmaceutical companies must navigate complex regulatory environments, which can delay the approval and launch of new drugs.

Impact of Precision Medicines

The shift towards precision medicines is changing the landscape of drug development. These medicines target specific patient populations, which can affect pricing strategies and market dynamics. For instance, drugs like Kalydeco, which target a small subset of cystic fibrosis patients, can command high prices due to their specificity and the lack of generic competition[3].

Global Market Trends

The global pharmaceutical market, including muscle relaxant drugs, is influenced by several trends:

Rise of Innovative Drug Delivery Technologies

Advancements in drug delivery technologies are enhancing the efficacy and safety of muscle relaxant drugs[4].

Growing Importance of Biotechnology and Customized Medicine

Biotechnology and customized medicine are becoming increasingly important, driving innovation in the pharmaceutical sector[4].

Governmental Support and Strategic Partnerships

Government support for innovation and strategic partnerships between pharmaceutical companies and contract manufacturing organizations (CMOs) are accelerating market expansion[4].

Key Takeaways

• The muscle relaxant drugs market is expected to grow significantly, driven by the rising geriatric population and increasing prevalence of chronic pain.
• Advancements in drug discovery and development are key drivers of this growth.
• Pharmaceutical companies face challenges such as generic competition, high development costs, and regulatory hurdles.
• The shift towards precision medicines is changing market dynamics and pricing strategies.
• Global trends such as innovative drug delivery technologies, biotechnology, and governmental support are shaping the market.

FAQs

Q: What is the projected market size of muscle relaxant drugs by 2032? A: The muscle relaxant drugs market is projected to reach USD 9.4 billion by 2032[1].

Q: What are the main drivers of growth in the muscle relaxant drugs market? A: The main drivers include the rising geriatric population, growing prevalence of chronic pain, and advancements in drug discovery and development[1].

Q: How do precision medicines impact the market dynamics of muscle relaxant drugs? A: Precision medicines can command high prices due to their specificity and the lack of generic competition, changing optimal pricing strategies and market dynamics[3].

Q: What are the major challenges faced by pharmaceutical companies in the muscle relaxant drugs market? A: The major challenges include generic competition, high development costs, and regulatory hurdles[2][3].

Q: How do global trends influence the muscle relaxant drugs market? A: Global trends such as innovative drug delivery technologies, biotechnology, and governmental support for innovation are driving market expansion[4].

Cited Sources

1. GMI Insights: Muscle Relaxant Drugs Market Size & Share Report, 2032.
2. Novartis: Condensed Interim Financial Report – Supplementary Data.
3. National Bureau of Economic Research: The Economics of Drug Development: Pricing and Innovation in a Changing Market.
4. Straits Research: Global Pharmaceutical Chemicals Market Size, Top Share, Report to 2032.
5. Cocrystal Pharma: Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Business Update.